Physician profile
John Michael Oblock
NPI 1427200724
$2,624.16
in general payments reported to CMS, 2019-2025
20 companies · $712 in 2025
The $712 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $116 · 2021: $244 · 2022: $362 · 2023: $551 · 2024: $301 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Entertainment: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.35 |
| Entertainment | $205.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $381.11 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $336.29 | 2019-2021 | |
| Alcon Vision LLC | $213.71 | 2022-2025 | Rhopressa, Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $209.50 | 2022-2025 | Miebo, Xiidra, Infuse |
| Optos, INC. | $205.13 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $189.74 | 2019-2025 | Misight Contact Lens |
| Abbvie INC. | $173.15 | 2022-2025 | |
| Rxsight INC | $166.08 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Sun Pharmaceutical Industries INC. | $165.75 | 2023-2025 | Cequa |
| Allergan, INC. | $154.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.51 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $63.86 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $58.05 | 2024 | Xdemvy |
| Glaukos Corporation | $49.76 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Mallinckrodt Hospital Products INC. | $34.99 | 2025 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $34.28 | 2022-2025 | |
| Horizon Therapeutics Plc | $22.96 | 2022 | |
| Amgen INC. | $22.81 | 2025 | Tepezza |
| Dompe US, INC. | $14.08 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oblock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.